Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology
ConclusionPAD exacerbations in the context of ICI treatment are common, although generally mild, and occur despite background immunosuppression. Exacerbations are more frequent and severe in patients on more intensive immunosuppressive therapies pre-immunotherapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Academia | Allergy & Immunology | Arthritis | Autoimmune Disease | Canada Health | Cancer | Cancer & Oncology | Corticosteroid Therapy | Immunotherapy | Inflammatory Bowel Disease | Lung Cancer | Melanoma | Psoriasis | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Skin Cancer | Study